INVO Bioscience

87 articles with INVO Bioscience

• INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd.

  1/15/2021

  - Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan - Seeks to expand access to infertility care in the fifth most populous country in the world, Pakistan, with approximately 212 million people

• INVO Bioscience Management Letter to Shareholders

  1/7/2021

    INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ('INVO"), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System, INVOcell®, an effective and a

• INVO Bioscience Forms Scientific Advisory Board with Leaders from Fertility Industry

  11/18/2020

  INVO Bioscience, Inc. (Nasdaq: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the formation of its Scientific Advisory Board (SAB) with the appointment of several prominent members of the fertility industry, including:

• INVO Bioscience Reports Third Quarter 2020 Financial Results

  11/16/2020

  INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the quarter ended September 30, 2020.

• INVO Bioscience Announces Pricing of Follow-on Public Offering and Listing on the NASDAQ Capital Market

  11/12/2020

  INVO Bioscience, Inc. (OTCQB: INVOD) (Nasdaq: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a public offering price of $3.20 per share.

• INVO Bioscience Establishes Joint Venture to Operate Dedicated INVOcell Fertility Clinics in Mexico

  9/30/2020

    INVO Bioscience, Inc. (OTCQB: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today it has teamed up with Dr. Francisco Arredondo , MD, a respected and experienced board

• INVO Bioscience Announces Appointment of Barbara Ryan and Matthew Szot to the Board of Directors

  9/16/2020

  INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the appointment of two seasoned executives, Barbara Ryan and Matthew Szot, to its board of directors, effective immediately

• INVO Bioscience Reports Second Quarter 2020 Financial Results

  8/13/2020

  Company to Provide Investor Update During Virtual Investor Conference on August 19 at 2:00pm ET (Details Below); Management Available for Virtual 1x1 Meetings

• INVO Bioscience to Present at the August 2020 Lytham Partners Virtual Investor Growth Conference

  8/6/2020

  INVO Bioscience, Inc. (OTCQB: INVO), ("the Company", "INVO") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, is scheduled to participate in a virtual presentation at the August 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, August 19, 2020

• INVO Bioscience Receives Registration Approval for INVOcell in Turkey

  7/16/2020

  - An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving - "As the world's only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility industry."   [16-July-2020]   SARASOTA, Fla. , July 16, 2020 /PRNewswire/ -- INVO Bioscience

• America Institute for Reproductive Medicine of Birmingham Alabama ("AIRM") Spotlights its Success in the Use of INVOcell

  7/2/2020

  INVO Bioscience, Inc. (OTCQB: INVO), ("the Company", "INVO") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,

• INVO Bioscience Announces Closing of Financing

  6/29/2020

   INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the second closing of its convertible note and unit purchase option private placement. The C

• INVO Bioscience Now Trading Under "INVO" Ticker Symbol On Tuesday, June 23, 2020

  6/23/2020

  INVO Bioscience, Inc. (OTCQB: INVO), ("the Company") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell ® , the world's only in vivo Intravaginal Culture System, announced that the company will trade under the symbol "INVO" effective at the beginning o

• A Vista Partners Interview with Steve Shum CEO of INVO Bioscience Regarding Increasing Access to Care for Fertility Treatment

  6/19/2020

  Today, Steve Shum , Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB: INVOD), a medical device company focused on creating alternative treatments for patie

• INVO Bioscience Announces 1-for-20 Reverse Stock Split

  5/22/2020

  INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today that it will effect a 1-for-20 reverse stock split, previously approved by the Company's Boa

• INVO Bioscience Reports First Quarter 2020 Financial Results

  5/15/2020

  INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the quarter ended March 31, 2020.

• INVO Bioscience Appoints Christopher Myer as VP Business Development - Americas

  4/2/2020

  INVO Bioscience, Inc. (OTCQB: INVO) , a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, announced today the appointment of Christopher A. Myer as Vice President Business Development - Americas. Mr. Myer will direct the Company's initiative to develop the INVO clinic business in the U

• INVO Bioscience Reports 2019 Financial Results

  3/30/2020

  INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the year ended December 31, 2019.

• INVO Bioscience Changes Trading Symbol to "INVO" Effective March 16, 2020

  3/16/2020

  INVO's novel, FDA-cleared INVOcell technology provides an in-vivo incubation solution which can help increase access and capacity to the large underserved global fertility market

• 

  BioSpace Movers & Shakers, March 13

  3/13/2020

  Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.